Publicaciones en colaboración con investigadores/as de London School of Hygiene & Tropical Medicine (146)

2024

  1. Secondary Prevention Therapies in Real-World Patients with Myocardial Infarction: Eligibility Based on Randomized Trials Supporting European and American Guidelines

    American Journal of Medicine, Vol. 137, Núm. 2, pp. 137-146.e10

  2. Twice-Daily Dosing of Dolutegravir in Infants on Rifampicin Treatment: A Pharmacokinetic Substudy of the EMPIRICAL Trial

    Clinical Infectious Diseases, Vol. 78, Núm. 3, pp. 702-710

2023

  1. A likelihood ratio approach for utilizing case-control data in the clinical classification of rare sequence variants: Application to BRCA1 and BRCA2

    Human Mutation, Vol. 2023

  2. Adeno-associated virus 2 infection in children with non-A–E hepatitis

    Nature, Vol. 617, Núm. 7961, pp. 555-563

  3. Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry

    Genome Medicine, Vol. 15, Núm. 1

  4. Biolimus-eluting vs. other limus-eluting stents in NSTE-ACS: A pooled analysis of GLASSY and TWILIGHT

    International Journal of Cardiology, Vol. 383, pp. 24-32

  5. Bleeding and Ischemic Risks of Ticagrelor Monotherapy After Coronary Interventions

    Journal of the American College of Cardiology, Vol. 82, Núm. 8, pp. 687-700

  6. Brief Report: Suboptimal Lopinavir Exposure in Infants on Rifampicin Treatment Receiving Double-dosed or Semisuperboosted Lopinavir/Ritonavir: Time for a Change

    Journal of Acquired Immune Deficiency Syndromes, Vol. 93, Núm. 1, pp. 42-46

  7. Clinically Driven Revascularization in High-Risk Patients Treated With Ticagrelor Monotherapy After PCI: Insights from the Randomized TWILIGHT Trial

    American Journal of Cardiology, Vol. 208, pp. 16-24

  8. Determinants of Progression and Regression of Subclinical Atherosclerosis Over 6 Years

    Journal of the American College of Cardiology, Vol. 82, Núm. 22, pp. 2069-2083

  9. Diagnosis of Multisystem Inflammatory Syndrome in Children by a Whole-Blood Transcriptional Signature

    Journal of the Pediatric Infectious Diseases Society, Vol. 12, Núm. 6, pp. 322-331

  10. Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention

    JACC: Cardiovascular Interventions, Vol. 16, Núm. 20, pp. 2514-2524

  11. Evaluating the Accuracy of Self-Collected Swabs for the Diagnosis of Mpox

    Clinical Infectious Diseases, Vol. 76, Núm. 7, pp. 1311-1314

  12. First-Line Antituberculosis Drug Concentrations in Infants With HIV and a History of Recent Admission With Severe Pneumonia

    Journal of the Pediatric Infectious Diseases Society, Vol. 12, Núm. 11, pp. 581-585

  13. Genetic signature detected in T cell receptors from patients with severe COVID-19

    iScience, Vol. 26, Núm. 10

  14. Genomic investigations of unexplained acute hepatitis in children

    Nature, Vol. 617, Núm. 7961, pp. 564-573

  15. Impact of 2018 EU Risk Minimisation Measures and Revised Pregnancy Prevention Programme on Utilisation and Prescribing Trends of Medicinal Products Containing Valproate: An Interrupted Time Series Study

    Drug Safety, Vol. 46, Núm. 7, pp. 689-702

  16. Impact of standard modifiable cardiovascular risk factors on 2-year all-cause mortality: Insights from an international cohort of 23,489 patients with acute coronary syndrome

    American Heart Journal, Vol. 264, pp. 20-30

  17. Impact of the MEESSI-AHF tool to guide disposition decision-making in patients with acute heart failure in the emergency department: A before-and-after study

    Emergency Medicine Journal, Vol. 41, Núm. 1, pp. 42-50

  18. Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial

    The Lancet Child and Adolescent Health, Vol. 7, Núm. 10, pp. 718-727